Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17014495 | 0.84 | ALDH1A1 (0.48) | SIGMAR1ALDH1A1CYP3A4MAPTADRA2A | |
| SCHEMBL17014372 | 0.77 | ALDH1A1 (0.48) | SIGMAR1ALDH1A1CYP3A4MAPTADRA2A | |
| SCHEMBL12260114 | 0.74 | ALDH1A1 (0.51) | SIGMAR1ALDH1A1CYP3A4MAPTADRA2A | |
| SCHEMBL11098135 | 0.74 | SIGMAR1 (0.41) | SIGMAR1ALDH1A1CYP3A4MAPTPNMT | |
| SCHEMBL8257850 | 0.73 | KCNH2 (0.41) | SIGMAR1ALDH1A1CYP3A4MAPTDRD2 | |
| SCHEMBL8437292 | 0.73 | DRD2 (0.47) | SIGMAR1CYP3A4DRD2DRD3KCNH2 | |
| SCHEMBL20955160 | 0.72 | SIGMAR1 (0.51) | SIGMAR1MAPTPNMTDRD2DRD3 | |
| SCHEMBL13167579 | 0.72 | ALDH1A1 (0.49) | SIGMAR1ALDH1A1CYP3A4MAPTHSD11B1 | |
| SCHEMBL10609283 | 0.72 | ALDH1A1 (0.46) | ALDH1A1CYP3A4MAPTHSD11B1SRD5A1 | |
| SCHEMBL11814847 | 0.71 | SIGMAR1 (0.47) | SIGMAR1CYP3A4PNMTDRD2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-8030322-B2 | Spirocompounds useful as modulators for dopamine D3 receptors | GLAXO GROUP LIMITED (GB) | 2011-10-04 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| WO-2007125061-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063078-A1 | SPIROCOMPOUNDS USEFUL AS MODULATORS FOR DOPAMINE D3 RECEPTORS | NR3C2, DRD3, TACR1 | SIGMAR1 9/4885ALDH1A1 2354/4885CYP3A4 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.